Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25377167 | 0.86 | TP53 (0.45) | YTHDC1CCR5ALDH1A1 | |
| SCHEMBL25377161 | 0.86 | TP53 (0.45) | YTHDC1CCR5ALDH1A1 | |
| SCHEMBL8905198 | 0.81 | TDP1 (0.41) | YTHDC1ACKR3MEN1KMT2AALDH1A1 | |
| SCHEMBL13240737 | 0.80 | ALDH1A1 (0.51) | YTHDC1LTA4HSLC6A2SLC6A4ACKR3 | |
| SCHEMBL1543215 | 0.80 | ALDH1A1 (0.51) | YTHDC1LTA4HSLC6A2SLC6A4ACKR3 | |
| Hydrochloric Acid SCHEMBL1543621 | 0.79 | ALDH1A1 (0.50) | YTHDC1LTA4HSLC6A2SLC6A4ACKR3 | |
| Hydrochloric Acid SCHEMBL1543620 | 0.79 | ALDH1A1 (0.50) | YTHDC1LTA4HSLC6A2SLC6A4ACKR3 | |
| SCHEMBL7426605 | 0.79 | ACKR3 (0.43) | LTA4HACKR3MEN1KMT2AALDH1A1 | |
| SCHEMBL12725478 | 0.78 | HSD11B1 (0.46) | MEN1KMT2A | |
| SCHEMBL9571701 | 0.78 | YTHDC1 (0.44) | YTHDC1SLC6A2SLC6A4ACKR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | YTHDC1 3451/4885LTA4H 121/4885NR1H2 403/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | YTHDC1 3451/4885LTA4H 121/4885NR1H2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.